Top

Published in:

01-12-2012 | Preclinical Study

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

Authors: María P. Roberti, Yamila S. Rocca, Mora Amat, María B. Pampena, José Loza, Federico Coló, Verónica Fabiano, Carlos M. Loza, Juan M. Arriaga, Michele Bianchini, María M. Barrio, Alicia I. Bravo, Enzo Domenichini, Reinaldo Chacón, José Mordoh, Estrella M. Levy

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Abstract

Triple-negative breast cancer (TNBC) patients do not benefit from target-specific treatments and is associated with a high relapse rate. Epidermal growth factor receptor is frequently expressed in TNBC and is a candidate for new therapies. In this work, we studied Cetuximab-mediated immune activity by NK cells. Thirteen activating/inhibitory receptors were examined on peripheral blood and tumor infiltrating NK cells. NK-cell functionality was evaluated using as effectors tumor-modulated NK cells and NK cells from patients. We evaluated the treatment with Cetuximab plus IL-2 or IL-15 in vivo in TNBC xenografts. Tumor NK-cells receptor profile showed upregulation of inhibitory receptors and downregulation of activating ones. Tumor-modulated NK cells were less cytotoxic. They could perform antibody-dependent cellular cytotoxicity (ADCC) triggered by Cetuximab, although impaired, it could still be restored by stimulation with IL-2 or IL-15. Patients with advanced disease displayed diminished levels of ADCC compared to healthy volunteers. ADCC was restored and potentiated with both cytokines, which were also effective in enhancing the therapeutic activity of Cetuximab in vivo. The combination of Cetuximab with IL-15 and IL-2 may be considered an attractive therapeutic approach to enhance the clinical efficacy of Cetuximab in TNBC.

Available only for authorised users

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. doi:10.1186/bcr2635 PubMedCrossRef

Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5–23. doi:10.1016/j.molonc.2010.11.003 PubMedCrossRef

van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161(6):1991–1996. doi:10.1016/S0002-9440(10)64476-8 PubMedCrossRef

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M (2009) Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116(2):317–328. doi:10.1007/s10549-008-0206-z PubMedCrossRef

Shin BK, Lee Y, Lee JB, Kim HK, Cho SJ, Kim A (2008) Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol Rep 19(3):617–625PubMed

Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA (2010) Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 17(Suppl 3):384–390. doi:10.1245/s10434-010-1260-4 PubMedCrossRef

Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683–692. doi:10.1038/nrclinonc.2010.154 PubMedCrossRef

Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160–1174. doi:10.1056/NEJMra0707704 PubMedCrossRef

Carey LA, Mayer E, Marcom PK et al (2007) TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Res Treat 106(Suppl 1):S32 (abstract 307)

10.

O’Shaughnessy J, Weckstein DJ, Vukelja SJ et al (2007) Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106(Suppl 1):S32 (abstract 308)

11.

Seton-Rogers S (2012) Immunotherapy: combinations that work. Nat Rev Cancer 12(4):231. doi:10.1038/nrc3250nrc3250 PubMedCrossRef

12.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510. doi:10.1038/ni1582 PubMedCrossRef

13.

Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N (2007) Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104(3):267–275. doi:10.1007/s10549-006-9416-4 PubMedCrossRef

14.

de Magalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E (2000) Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 23(1):154–160CrossRef

15.

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13(1):98–107. doi:10.3109/14653249.2010.515582 PubMedCrossRef

16.

Leibson PJ (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6(6):655–661PubMedCrossRef

17.

Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N (2008) Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol 27(3):93–110. doi:10.1080/08830180801911743 PubMedCrossRef

18.

Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25(2):331–342. doi:10.1016/j.immuni.2006.06.013 PubMedCrossRef

19.

Levy EM, Roberti MP, Mordoh J (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011:676198. doi:10.1155/2011/676198 PubMedCrossRef

20.

Meazza R, Azzarone B, Orengo AM, Ferrini S (2011) Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011:861920. doi:10.1155/2011/861920 PubMedCrossRef

21.

Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99(5):937–943. doi:10.1172/JCI119258 PubMedCrossRef

22.

Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100(10):3633–3638. doi:10.1182/blood-2001-12-0293 PubMedCrossRef

23.

Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT (2008) Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transpl 14(3):290–300. doi:10.1016/j.bbmt.2007.12.490 CrossRef

24.

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM (2011) IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 130(2):465–475. doi:10.1007/s10549-011-1360-2 PubMedCrossRef

25.

Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, Lema B, Schiaffi J, Yomha R, Mordoh J (1991) Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19(1):47–56PubMedCrossRef

26.

Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa I, Bolondi A, Ayala M, Mordoh J (1998) The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol (Noisy-le-grand) 44(3):493–504

27.

Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112(4):863–875. doi:10.1002/cncr.23239 PubMedCrossRef

28.

Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183(8):4921–4930. doi:10.4049/jimmunol.0901226 PubMedCrossRef

29.

Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF, Fridman WH, Sautes-Fridman C, Cremer I (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422. doi:10.1158/0008-5472.CAN-10-4179 PubMedCrossRef

30.

Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121(9):3609–3622. doi:10.1172/JCI4581645816 PubMedCrossRef

31.

Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, Huertas E, Sanchez Loria F, Pairola A, Bianchini M, Mordoh J, Levy EM (2012) Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun. doi:10.1177/1753425912453187 PubMed

32.

Roberti MP, Arriaga JM, Bianchini M, Quinta HR, Bravo AI, Levy EM, Mordoh J, Barrio MM (2012) Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther 13(11):1123–1140PubMedCrossRef

33.

Chacon RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12(Suppl 2):S3. doi:10.1186/bcr2574 PubMedCrossRef

34.

Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A (2006) Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24(18):2866–2872. doi:10.1200/JCO.2005.04.3547 PubMedCrossRef

35.

Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–5577. doi:10.1200/JCO.2005.07.119 PubMedCrossRef

36.

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208. doi:10.18210.1200/JCO.2004.10.182 PubMedCrossRef

37.

Baselga J, Stemmer S, Pego A, Chan A, Goeminne J C, Graas M P, et al. (2010) Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triplenegative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 70: Abstr PD01–01

38.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. doi:10.1200/JCO.2010.34.5579

39.

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G (2011) Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 17(19):6329–6337. doi:10.1158/1078-0432.CCR-11-1081 PubMedCrossRef

40.

Fehniger TA, Cooper MA, Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13(2):169–183PubMedCrossRef

41.

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer. November 25, 2009. http://www.clinicaltrials.gov/show/NCT01021059

42.

Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd (2012) Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother 35(5):367–373. doi:10.1097/CJI.0b013e3182562d76 PubMedCrossRef

43.

Abes R, Teillaud JL (2011) Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev 30(1):111–124. doi:10.1007/s10555-011-9282-3 PubMedCrossRef

44.

Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44(16):3823–3837. doi:10.1016/j.molimm.2007.06.151 PubMedCrossRef

45.

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527. doi:10.1038/nm1764 PubMedCrossRef

46.

Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71(21):6621–6632. doi:10.1158/0008-5472.CAN-11-0792 PubMedCrossRef

47.

Beziat V, Descours B, Parizot C, Debre P, Vieillard V (2010) NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS ONE 5(8):e11966. doi:10.1371/journal.pone.0011966 PubMedCrossRef

48.

Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin RS (2012) Rapid development of exhaustion and downregulation of eomesodermin limits the anti-tumor activity of adoptively transferred murine natural killer cells. Blood. doi:10.1182/blood-2012-03-415364

49.

Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, Honorato B, Bitarte N, Garcia-Foncillas J (2012) Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 12:1774–1780. doi:10.1016/j.ejca.2012.01.007 CrossRef

50.

Grob TJ, Heilenkotter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A (2012) Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-012-2092-7 PubMed

51.

Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E (2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10:136. doi:10.1186/1471-2407-10-136 PubMedCrossRef

52.

Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N (1981) In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127(1):34–38PubMed

Title: IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Authors: María P. Roberti
Yamila S. Rocca
Mora Amat
María B. Pampena
José Loza
Federico Coló
Verónica Fabiano
Carlos M. Loza
Juan M. Arriaga
Michele Bianchini
María M. Barrio
Alicia I. Bravo
Enzo Domenichini
Reinaldo Chacón
José Mordoh
Estrella M. Levy
Publication date: 01-12-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2287-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Phase II open-label study of sunitinib in patients with advanced breast cancer

Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer

Plasma matrix metalloproteinases and postmenopausal breast cancer risk: a nested case–control study in the Multiethnic Cohort study

Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer